10-KPeriod: FY2001

PFIZER INC Annual Report, Year Ended Dec 31, 2001

Filed March 28, 2002For Securities:PFE

Summary

Pfizer Inc.'s 2001 10-K filing highlights a robust performance driven primarily by its Pharmaceuticals segment, which accounted for 79% of total revenues. The company reported significant growth in key therapeutic areas, with eight blockbuster human pharmaceutical products (Lipitor, Norvasc, Zoloft, Neurontin, Viagra, Zithromax, Celebrex, and Diflucan) generating 76% of the segment's revenue and growing at a combined rate of 17%. The merger with Warner-Lambert in June 2000 continues to be a significant factor, contributing to the company's expanded portfolio and market reach. Despite strong performance, Pfizer faces ongoing challenges including increasing pricing pressures, generic competition, and evolving regulatory landscapes. Investment in research and development remains a core strategy, with significant expenditures totaling $4.8 billion in 2001, aimed at fueling a pipeline of over 160 projects in development. The company is actively expanding its R&D facilities to support this innovation pipeline. While the company acknowledges potential risks related to patent expirations, litigation, and international currency fluctuations, its diversified business segments and strong product portfolio position it for continued growth, albeit with an awareness of the competitive and regulatory pressures in the global pharmaceutical market.

Key Highlights

  • 1The Pharmaceuticals segment is the primary revenue driver, contributing 79% of total revenues in 2001, up from 77% in 2000 and 74% in 1999.
  • 2Eight key human pharmaceutical products (Lipitor, Norvasc, Zoloft, Neurontin, Viagra, Zithromax, Celebrex, and Diflucan) generated 76% of pharmaceutical revenues and grew by 17% in 2001.
  • 3Pfizer invested $4.8 billion in Research and Development in 2001, with over 160 projects in development, underscoring a commitment to innovation.
  • 4The merger with Warner-Lambert in June 2000 has been fully integrated, with financial statements restated to reflect the combined entity.
  • 5International operations accounted for 38% of total revenues ($12.3 billion) in 2001, with Japan being the largest single international market (7% of total revenues).
  • 6The company faces significant patent litigation risks, with challenges to patents for key products like Zoloft, Neurontin, and Diflucan.
  • 7Despite a decline in Animal Health revenues in 2001, strategic restructuring and new promotional practices are expected to drive future growth, with over 40 programs in development.

Frequently Asked Questions

Pfizer's top revenue generators in 2001 were eight human pharmaceutical products: Lipitor, Norvasc, Zoloft, Neurontin, Viagra, Zithromax, Celebrex, and Diflucan. These products accounted for 76% of the Pharmaceuticals segment's revenue and collectively grew by 17%.

Pfizer demonstrates a strong commitment to innovation, investing approximately $4.8 billion in Research and Development in 2001. The company has over 160 projects in various stages of development and is actively expanding its R&D facilities.

Key risks and challenges include increasing pricing pressures in the pharmaceutical market, intense competition from generic drug manufacturers (with patent expirations for major drugs approaching), ongoing patent litigation, potential regulatory changes (especially concerning Medicare and Medicaid in the U.S. and price controls in international markets), and currency fluctuations impacting international revenues. The company is also managing litigation related to past products like Rezulin and asbestos claims.

The merger with Warner-Lambert, completed in June 2000, has been accounted for as a pooling of interests, and all prior financial statements have been restated to reflect the combined entity. This merger has expanded Pfizer's product portfolio and market reach, contributing to its overall performance.